Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Antonina G. Aydanian"'
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e106699 (2014)
Monoclonal antibodies are important tools in research and since the 1990s have been an important therapeutic class targeting a wide variety of diseases. Earlier methods of mAb production relied exclusively on the lengthy process of making hybridomas.
Externí odkaz:
https://doaj.org/article/81542b1db53c4071bc00d813cad542b5
Autor:
Emily Y. Jen, Jiang Liu, Lei Nie, Jee Eun Lee, Kelly J. Norsworthy, Ann T. Farrell, Donna Przepiorka, Pedro L. Del Valle, Charles Jewell, Antonina G. Aydanian, Chia-Wen Ko, Richard Pazdur, Christopher M. Sheth, Marjorie A. Shapiro
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(14)
On September 1, 2017, the FDA granted approval for gemtuzumab ozogamicin (Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a monotherapy for the treatment of adult patients with newly diagnosed CD33-positive acute myeloid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e116f2798cff476caeef820993cec972
https://pubmed.ncbi.nlm.nih.gov/29476018
https://pubmed.ncbi.nlm.nih.gov/29476018
Publikováno v:
BMC Immunology
Background The naïve antibody repertoire is initially dependent upon the number of germline V(D)J genes and the ability of recombined heavy and light chains to pair. Individual VH and VL genes are not equally represented in naïve mature B cells, su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b0269d54aaa192551bc856985a69e1